Case Study: Nobelpharma America launches HYFTOR for rare genetic disorder treatment with JPA Health

Nobelpharma America launches HYFTOR with JPA Health and reaches 201.5M impressions

Nobelpharma America turned to JPA Health to brand and launch its first U.S. product, HYFTOR. The challenge was that facial angiofibroma, a condition associated with tuberous sclerosis complex, was consistently deprioritized as a treatable condition despite its significant emotional impact on patients.

JPA Health developed the "my VICTORY" campaign, a memorable brand story that brought to life the product’s unique position in the market and its benefits. The solution included a full stable of paid, earned, and owned assets. The campaign's impact resulted in 74 new HYFTOR prescribers in two months, over 201 million campaign impressions, and a potential audience reach of 500,000.

Nobelpharma America